OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today it has entered into a manufacturing and supply agreement with
Optibiotix Health CEO Stephen O’Hara commented “High blood pressure and high cholesterol are significant risk factors in cardiovascular disease. Numerous scientific studies have shown that In combination these factors work together
OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on 1 January 2018. Adam
Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI) for
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it intends to convene a General Meeting to
Food Matters Live has announced the winners of its inaugural awards, which celebrate the incredible innovation that continues to shape the future of food and drink. These awards recognize the
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care gave DirectorsTalk the following product development and commercial update on its
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today it has entered into a manufacturing and supply agreement
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced this morning that it will be presenting research data on its microbiome modulators at MicroBiome R&D and Business Collaboration (USA) in San Diego, on 2-3
Stephen O’Hara, CEO of OptiBiotix, talks to DirectorsTalk about the 3 year supply agreeement: “We are pleased to announce this agreement with Galenicum which expands sales of LP(LDL) (R) into
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
